Multiple targetable genetic alterations have been identified in patients with NSCLC affecting the EGFR, KRAS, BRAF, PIK3CA, ALK, ROS1, NRAS, and MET genes among others (5). This evidence concerns the gene MET and non-small cell lung carcinoma.